ETON

Eton Pharmaceuticals, Inc.

NasdaqGMUSDEQUITY DELAYED

63.80

▲ 3.89 (6.49%)

MARKET · —

Price

Open

58.01

Prev close

59.91

Day high

63.56

Day low

59.76

Volume

619.78K

Market cap

—

P/E (TTM)

—

52W range

14.27 – 64.00

Trailing performance

Price return · vs SPY

Returnvs SPY

+7.83% +9.2%

+43.79% +40.1%

+81.34% +78.2%

+253.99% +242.9%

YTD

+275.34% +263.1%

+283.50% +263.5%

+1,362.44% +1,288.3%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

53.70

+18.81% from price

SMA 20

49.86

+27.29% from price

SMA 50

42.04

+50.99% from price

SMA 100

35.07

+81.90% from price

SMA 200

26.09

+143.26% from price

EMA 12

54.98

+16.04% from price

EMA 26

49.38

+29.21% from price

EMA 50

43.88

+45.40% from price

RSI (14)

73.7

Overbought

MACD (12,26,9)

5.60

Hist 1.57

ATR (14)

4.19

6.60% of price

Realised vol 30D

121.1%

Annualised

Bollinger upper

65.70

20, 2σ

Bollinger lower

34.02

20, 2σ

50 / 200 cross

Golden

42.04 vs 26.09

Trend bias

Above 200

+143.26%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.15

Less volatile than market

Correlation to SPY

0.03

Largely independent

Realised vol 30D

121.1%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-36.2%

Peak to trough

Max drawdown 5Y

-69.3%

Peak to trough

ATR 14

4.19

6.60% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 63.80

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

ETON · links out to the publisher

Three Biotech Stocks Stick Out With Their Stellar Charts Investor's Business Daily · 1d ago Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript Motley Fool · 2d ago Is Eton Pharmaceuticals (ETON) Fully Priced On Strong Q2 Results And Raised Guidance? Simply Wall St. · 8d ago Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High Investor's Business Daily · 8d ago Sector Update: Healthcare Stocks Decline Late Afternoon MT Newswires · 8d ago Why Eton Pharmaceuticals Is Top of the Class Today Motley Fool · 8d ago This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day Stocktwits · 8d ago Top Midday Gainers MT Newswires · 8d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.